JP2024517085A5 - - Google Patents

Info

Publication number
JP2024517085A5
JP2024517085A5 JP2023562607A JP2023562607A JP2024517085A5 JP 2024517085 A5 JP2024517085 A5 JP 2024517085A5 JP 2023562607 A JP2023562607 A JP 2023562607A JP 2023562607 A JP2023562607 A JP 2023562607A JP 2024517085 A5 JP2024517085 A5 JP 2024517085A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
therapeutically effective
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024079 external-priority patent/WO2022221143A1/en
Publication of JP2024517085A publication Critical patent/JP2024517085A/ja
Publication of JP2024517085A5 publication Critical patent/JP2024517085A5/ja
Pending legal-status Critical Current

Links

JP2023562607A 2021-04-12 2022-04-08 子宮漿液性がんを治療するためのｗｅｅ１化合物 Pending JP2024517085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163174005P 2021-04-12 2021-04-12
US202163174004P 2021-04-12 2021-04-12
US63/174,005 2021-04-12
US63/174,004 2021-04-12
PCT/US2022/024079 WO2022221143A1 (en) 2021-04-12 2022-04-08 Wee1 compound for treating uterine serous carcinoma

Publications (2)

Publication Number Publication Date
JP2024517085A JP2024517085A (ja) 2024-04-19
JP2024517085A5 true JP2024517085A5 (https=) 2025-04-09

Family

ID=83640600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562607A Pending JP2024517085A (ja) 2021-04-12 2022-04-08 子宮漿液性がんを治療するためのｗｅｅ１化合物

Country Status (7)

Country Link
US (1) US20240197743A1 (https=)
EP (1) EP4322958A4 (https=)
JP (1) JP2024517085A (https=)
AU (1) AU2022259496A1 (https=)
CA (1) CA3213804A1 (https=)
TW (1) TW202304455A (https=)
WO (1) WO2022221143A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
WO2022011391A1 (en) 2020-07-09 2022-01-13 Recurium Ip Holdings, Llc Salts and forms of a wee1 inhibitor
CN120475974A (zh) * 2022-11-08 2025-08-12 芝诺管理公司 阿森色替（azenosertib）在治疗癌症中的间歇性给药方案

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566612A3 (en) * 2018-03-09 2025-08-20 Recurium IP Holdings, LLC Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
US12318452B2 (en) 2018-09-27 2025-06-03 Dana-Farber Cancer Institute, Inc. Degraders of WEE1 kinase
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Similar Documents

Publication Publication Date Title
JP2024517085A5 (https=)
JP2024074963A5 (https=)
RU2012106620A (ru) Комбинации и способы введения терапевтических средств и комбинированной терапии
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2022537551A5 (https=)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2025509510A5 (https=)
JP2018507243A5 (https=)
JP2020516646A5 (https=)
JP2022188083A5 (https=)
JP2021509395A5 (https=)
JP2015500822A5 (https=)
JP2022525549A5 (https=)
JP2022523530A5 (https=)
JP2010538066A5 (https=)
JP2024016209A5 (https=)
JP2019524820A5 (https=)
RU2007101686A (ru) Комбинированная композиция
RU2005126819A (ru) Усовершенствованное лечение опухолей
JP2016505050A5 (https=)
JP2019513706A5 (https=)
JP2022177119A5 (https=)
JP2010504307A5 (https=)
JP2023501317A5 (https=)
CN116113411A (zh) 用于治疗软组织肉瘤的联用药物